Guliz A. Barkan

Guliz A. Barkan

Auto-generated profile, based on publicly available information

Guliz A. Barkan

Department of Pathology and Laboratory Medicine Loyola University Healthcare System Maywood Illinois USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2013 in Cancer Cytopathology
Verified
Journal Article
Open access
PDF file
JUJulianne Muus Ubago
Julianne Muus Ubago
VMVikas Mehta
Vikas Mehta
EWEva M. Wojcik
Eva M. Wojcik
GBGüliz A. Barkan
Güliz A. Barkan
BACKGROUND: In urine cytology, the diagnosis of atypia is subjective and clinical management based on these results can be difficult to determine. In this study, the authors determined the percentage of atypical urine diagnoses that progressed to positive cytology or surgical pathology results over an 11‐year period.METHODS: In a retrospective review of the authors’ institution, 1320 atypical urine cytology diagnoses were identified in specimens from 851 patients obtained from January 2000 through December 2010. All subsequent pathology reports were reviewed to determine which patients developed positive cytology/surgical pathology diagnoses. In total, 4106 cytology and surgical pathology specimen reports were reviewed.RESULTS: At the authors’ institution, 1320 of 16,299 of urine cytology specimens (8.1%) were diagnosed as atypical during the 11‐year period. Overall, 271 of 1320 initial atypical urine specimens (21%) progressed to positive cytology or surgical pathology results with a mean time to progression of 155 days. Of the cases that progressed to malignancy, 118 were high‐grade urothelial carcinoma and 92 were low‐grade urothelial carcinoma.CONCLUSIONS: The rate of atypia in urine specimens at this institution was 8.1%. Of the specimen types, atypia was the most common in urinary diversion specimens (16%) and the least common in upper tract cytology (3.8%). When diagnosed as atypical, upper tract specimens had the highest percentage of progression to high‐grade carcinoma. Therefore, the authors concluded that the diagnosis of atypia in this specimen group has higher clinical significance and should be managed more aggressively. Cancer (Cancer Cytopathol) 2013;121:387–391. © 2013 American Cancer Society.

3 May 2019 in Cancer Cytopathology
Verified
Journal Article
Open access
PDF file
ZMZahra Maleki
Zahra Maleki
ZBZubair Baloch
Zubair Baloch
RLRyan Lu
Ryan Lu
KSKhurram Shafique
Khurram Shafique
SSSharon J. Song
Sharon J. Song
Marc PusztaszeriMarc Pusztaszeri
Marc Pusztaszeri
Background: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is a 6‐tier diagnostic category system with associated risks of malignancy (ROMs) and management recommendations. Submandibular gland fine‐needle aspiration (FNA) is uncommon with a higher frequency of inflammatory lesions and a higher relative proportion of malignancy, and this may affect the ROM and subsequent management. This study evaluated the application of the MSRSGC and the ROM for each diagnostic category for 734 submandibular gland FNAs.Methods: Submandibular gland FNA cytology specimens from 15 international institutions (2013‐2017) were retrospectively assigned to an MSRSGC diagnostic category as follows: nondiagnostic, nonneoplastic, atypia of undetermined significance (AUS), benign neoplasm, salivary gland neoplasm of uncertain malignant potential (SUMP), suspicious for malignancy (SM), or malignant. A correlation with the available histopathologic follow‐up was performed, and the ROM was calculated for each MSRSGC diagnostic category.Results: The case cohort of 734 aspirates was reclassified according to the MSRSGC as follows: nondiagnostic, 21.4% (0%‐50%); nonneoplastic, 24.2% (9.1%‐53.6%); AUS, 6.7% (0%‐14.3%); benign neoplasm, 18.3% (0%‐52.5%); SUMP, 12% (0%‐37.7%); SM, 3.5% (0%‐12.5%); and malignant, 13.9% (2%‐31.3%). The histopathologic follow‐up was available for 333 cases (45.4%). The ROMs were as follows: nondiagnostic, 10.6%; nonneoplastic, 7.5%; AUS, 27.6%; benign neoplasm, 3.2%; SUMP, 41.9%; SM, 82.3%; and malignant, 93.6%.Conclusions: This multi‐institutional study shows that the ROM of each MSRSGC category for submandibular gland FNA is similar to that reported for parotid gland FNA, although the reported rates for the different MSRSGC categories were variable across institutions. Thus, the MSRSGC can be reliably applied to submandibular gland FNA.

1 March 2015 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
JPJennifer Prather
Jennifer Prather
BABrent Arville
Brent Arville
GCGrazina Chatt
Grazina Chatt
SPStefan E. Pambuccian
Stefan E. Pambuccian
EWEva M. Wojcik
Eva M. Wojcik
GBGüliz A. Barkan
Güliz A. Barkan

7 August 2020 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
DADerek B Allison
Derek B Allison
ASAlexander P. Smith
Alexander P. Smith
DADaniel An
Daniel An
JMJames Adam Miller
James Adam Miller
KSKhurram Shafique
Khurram Shafique
ZMZahra Maleki
Zahra Maleki

8 April 2020 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
DJDaniel N. Johnson
Daniel N. Johnson
MOMine Onenerk
Mine Onenerk
JKJeffrey F. Krane
Jeffrey F. Krane
EREsther Diana Rossi
Esther Diana Rossi
ZBZubair Baloch
Zubair Baloch
WFWilliam Faquin
William Faquin

17 November 2023 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
EREsther Diana Rossi
Esther Diana Rossi
ZBZubair Baloch
Zubair Baloch
GBGuliz Barkan
Guliz Barkan
MFMaria Pia Foschini
Maria Pia Foschini
DIDaniel F. I. Frank Iyama-Kurtycz
Daniel F. I. Frank Iyama-Kurtycz
WFWilliam Faquin
William Faquin